{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:53:07Z","timestamp":1791514387743,"version":"4.3.4"},"update-to":[{"DOI":"10.1371\/journal.pntd.0011567","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000}}],"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1201530"],"award-info":[{"award-number":["OPP1201530"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH","award":["K08AI121422"],"award-info":[{"award-number":["K08AI121422"]}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Moxidectin (MOX) is a milbemycin endectocide recently approved by the U.S. FDA for the treatment of onchocerciasis in persons at least 12 years of age. MOX has been shown to have a good safety profile in recent clinical trials. The efficacy of MOX for the treatment of lymphatic filariasis (LF) and its potential use in mass drug administration protocols for the elimination of LF is currently under evaluation. In the context of a clinical trial, we investigated the pharmacokinetics and drug interactions of a combination of MOX plus albendazole (ALB) with or without diethylcarbamazine (DEC) compared to ivermectin (IVM) plus ALB with or without DEC in the following four different treatment arms: (I) IVM (0.2mg\/kg) plus DEC (6 mg\/kg) and ALB (400mg); (II) IVM plus ALB; (III) MOX (8 mg) plus DEC and ALB; and (IV) MOX plus ALB. Drug concentrations were determined using validated liquid chromatography-mass spectrometric methods. Pharmacokinetic parameters were determined using standard non-compartmental analysis methods. Statistical analysis was performed using JMP software. Fifty-eight of 164 study participants (53 men and five women) were included with ages ranging from 18 to 63 yrs (mean = 37). MOX apparent oral clearance (Cl\/F) ranged from 0.7 to 10.8 L\/hr with C<jats:sub>max<\/jats:sub> values ranging from 20.8 to 314.5 ng\/mL. The mean (range) area under the curve (AUC)<jats:sub>0-\u221e<\/jats:sub> for MOX, 3405 ng*hr\/mL (742\u201311376), and IVM 1906 ng*hr\/mL (692\u20135900), varied over a ~15.3 and ~8.5-fold range, respectively. The geometric mean ratio for C<jats:sub>max<\/jats:sub>, AUC<jats:sub>0\u2013t<\/jats:sub>, and AUC<jats:sub>0\u2013\u221e<\/jats:sub> were within the no-drug interaction range of 80\u2013125% for all drugs. This indicates that the addition of MOX to ALB alone or ALB plus DEC for LF therapy did not alter the drug exposure of co-administered drugs compared to IVM combinations.<\/jats:p>\n<jats:p><jats:bold>Clinical Trial Registration<\/jats:bold>: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04410406\" xlink:type=\"simple\">NCT04410406<\/jats:ext-link>, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/\" xlink:type=\"simple\">https:\/\/clinicaltrials.gov\/<\/jats:ext-link>.<\/jats:p>","DOI":"10.1371\/journal.pntd.0011567","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T17:51:50Z","timestamp":1692899510000},"page":"e0011567","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetics of Moxidectin combined with Albendazole or Albendazole plus Diethylcarbamazine for Bancroftian Filariasis"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6455-5388","authenticated-orcid":true,"given":"Yashpal S.","family":"Chhonker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bjerum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veenu","family":"Bala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allassane F.","family":"Ouattara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin G.","family":"Koudou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toki P.","family":"Gabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoulaye","family":"Me\u00eft\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter U.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Budge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4169-5027","authenticated-orcid":true,"given":"Daryl J.","family":"Murry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"issue":"2","key":"pntd.0011567.ref001","first-page":"135","article-title":"Lymphatic filariasis: diagnosis and pathogenesis. WHO expert committee on filariasis","volume":"71","year":"1993","journal-title":"Bull World Health Organ"},{"issue":"40","key":"pntd.0011567.ref002","first-page":"589","article-title":"Summary of global update on preventive chemotherapy implementation in 2016: crossing the billion","volume":"92","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"issue":"12","key":"pntd.0011567.ref003","doi-asserted-by":"crossref","first-page":"e3328","DOI":"10.1371\/journal.pntd.0003328","article-title":"Global programme to eliminate lymphatic filariasis: the processes underlying programme success.","volume":"8","author":"K Ichimori","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pntd.0011567.ref004","first-page":"491","article-title":"Strategies and tools for the control\/elimination of lymphatic filariasis","volume":"75","author":"EA Ottesen","year":"1997","journal-title":"Bulletin of the world Health Organization"},{"key":"pntd.0011567.ref005","year":"2016","journal-title":"Global programme to eliminate lymphatic filariasis: progress report"},{"key":"pntd.0011567.ref006","first-page":"196","volume-title":"Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021\u20132030","author":"MM Ntuli","year":"2021"},{"key":"pntd.0011567.ref007","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0065-308X(05)61010-X","article-title":"Lymphatic filariasis: treatment, control and elimination","volume":"61","author":"EA Ottesen","year":"2006","journal-title":"Advances in parasitology"},{"issue":"19","key":"pntd.0011567.ref008","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A Trial of a Triple-Drug Treatment for Lymphatic Filariasis","volume":"379","author":"CL King","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"pntd.0011567.ref009","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis","volume":"62","author":"EK Thomsen","year":"2016","journal-title":"Clinical Infectious Diseases"},{"issue":"7","key":"pntd.0011567.ref010","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1093\/cid\/ciz1050","article-title":"Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in C\u00f4te d\u2019Ivoire: An Open-label Randomized Controlled Trial","volume":"71","author":"CM Bjerum","year":"2019","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"pntd.0011567.ref011","doi-asserted-by":"crossref","first-page":"e0007325","DOI":"10.1371\/journal.pntd.0007325","article-title":"Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in C\u00f4te d\u2019Ivoire.","volume":"13","author":"C Edi","year":"2019","journal-title":"PLOS Neglected Tropical Diseases"},{"issue":"3","key":"pntd.0011567.ref012","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis","volume":"62","author":"EK Thomsen","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pntd.0011567.ref013","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1473-3099(16)30467-4","article-title":"Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study","volume":"17","author":"MA Irvine","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"pntd.0011567.ref014","unstructured":"2017. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29565523."},{"issue":"4","key":"pntd.0011567.ref015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4269\/ajtmh.2008.79.480","article-title":"Determinants of success in national programs to eliminate lymphatic filariasis: a perspective identifying essential elements and research needs","volume":"79","author":"D Kyelem","year":"2008","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"pntd.0011567.ref016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-3305-7-363","article-title":"Multidimensional complexities of filariasis control in an era of large-scale mass drug administration programmes: a can of worms.","volume":"7","author":"DH Molyneux","year":"2014","journal-title":"Parasites & vectors"},{"key":"pntd.0011567.ref017","volume-title":"First new treatment for river blindness approved by U.S. FDA in 20 years 2018","author":"TDR","year":"2018"},{"issue":"10154","key":"pntd.0011567.ref018","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(17)32844-1","article-title":"Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial","volume":"392","author":"NO Opoku","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"pntd.0011567.ref019","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1177\/0091270003257456","article-title":"The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans","volume":"43","author":"MM Cotreau","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"pntd.0011567.ref020","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4269\/ajtmh.2012.11-0415","article-title":"The effect of a high-fat breakfast on the pharmacokinetics of moxidectin in healthy male subjects: a randomized phase I trial","volume":"86","author":"JM Korth-Bradley","year":"2012","journal-title":"Am J Trop Med Hyg"},{"issue":"8","key":"pntd.0011567.ref021","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S1473-3099(18)30233-0","article-title":"Efficacy and tolerability of moxidectin alone and in co-administration with albendazole and tribendimidine versus albendazole plus oxantel pamoate against Trichuris trichiura infections: a randomised, non-inferiority, single-blind trial","volume":"18","author":"B Barda","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"pntd.0011567.ref022","first-page":"1193","article-title":"Efficacy and Safety of Ascending Dosages of Moxidectin and Moxidectin-albendazole Against Trichuris trichiura in Adolescents: A Randomized Controlled Trial","volume":"70","author":"L Keller","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pntd.0011567.ref023","article-title":"Efficacy and safety of moxidectin and albendazole compared with ivermectin and albendazole coadministration in adolescents infected with Trichuris trichiura in Tanzania: an open-label, non-inferiority, randomised, controlled, phase 2\/3 trial","author":"S Welsche","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"pntd.0011567.ref024","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jpba.2017.12.037","article-title":"LC-MS\/MS method for simultaneous determination of diethylcarbamazine, albendazole and albendazole metabolites in human plasma: Application to a clinical pharmacokinetic study","volume":"151","author":"YS Chhonker","year":"2018","journal-title":"J Pharm Biomed Anal"},{"issue":"22","key":"pntd.0011567.ref025","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.4155\/bio-2018-0110","article-title":"A sensitive and selective LC\u2013MS\/MS method for quantitation of ivermectin in human, mouse and monkey plasma: clinical validation.","volume":"10","author":"YS Chhonker","year":"2018","journal-title":"Bioanalysis"},{"issue":"2","key":"pntd.0011567.ref026","doi-asserted-by":"crossref","first-page":"e4389","DOI":"10.1002\/bmc.4389","article-title":"Bioanalytical method development and validation of moxidectin in plasma by LC\u2013MS\/MS: Application to in vitro metabolism","volume":"33","author":"YS Chhonker","year":"2019","journal-title":"Biomedical Chromatography"},{"key":"pntd.0011567.ref027","article-title":"Pharmacokinetic and safety study of co-administration of albendazole, diethylcarbamazine, Ivermectin and azithromycin for the integrated treatment of Neglected Tropical Diseases","author":"LN John","year":"2020","journal-title":"Clinical Infectious Diseases"},{"key":"pntd.0011567.ref028","author":"European Medicines Agenc","year":"2010","journal-title":"Guideline on the Investigation of Bioequivalence"},{"key":"pntd.0011567.ref029","author":"and RCfD","year":"2019","journal-title":"Statistical Approaches to Establishing Bioequivalence. 2019"},{"issue":"5","key":"pntd.0011567.ref030","doi-asserted-by":"crossref","first-page":"e2221","DOI":"10.1371\/journal.pntd.0002221","article-title":"A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali.","volume":"7","author":"YI Coulibaly","year":"2013","journal-title":"PLoS neglected tropical diseases."},{"issue":"3","key":"pntd.0011567.ref031","doi-asserted-by":"crossref","first-page":"e0010005","DOI":"10.1371\/journal.pntd.0010005","article-title":"Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection.","volume":"16","author":"B Tan","year":"2022","journal-title":"PLOS Neglected Tropical Diseases"},{"issue":"6","key":"pntd.0011567.ref032","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/cts.12583","article-title":"Evaluation of the Cardiac Safety of Long-Acting Endectocide Moxidectin in a Randomized Concentration-QT Study.","volume":"11","author":"SA Kinrade","year":"2018","journal-title":"Clinical and Translational Science"},{"issue":"2","key":"pntd.0011567.ref033","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1179\/000349803235001697","article-title":"The co-administration of ivermectin and albendazole-safety, pharmacokinetics and efficacy against Onchocerca volvulus.","volume":"97","author":"K Awadzi","year":"2003","journal-title":"Annals of Tropical Medicine & Parasitology"},{"issue":"1","key":"pntd.0011567.ref034","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejps.2006.10.004","article-title":"Interaction of macrocyclic lactones with P-glycoprotein: Structure\u2013affinity relationship","volume":"30","author":"A Lespine","year":"2007","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"4","key":"pntd.0011567.ref035","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1124\/dmd.109.030700","article-title":"Role of P-Glycoprotein in the Disposition of Macrocyclic Lactones: A Comparison between Ivermectin, Eprinomectin, and Moxidectin in Mice","volume":"38","author":"S Kiki-Mvouaka","year":"2010","journal-title":"Drug Metabolism and Disposition"},{"issue":"5","key":"pntd.0011567.ref036","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1023\/A:1010686508307","article-title":"In vitro metabolism of 14C-moxidectin by hepatic microsomes from various species","volume":"25","author":"J Dupuy","year":"2001","journal-title":"Vet Res Commun"},{"issue":"2","key":"pntd.0011567.ref037","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/cpdd.81","article-title":"Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects","volume":"3","author":"JM Korth-Bradley","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"pntd.0011567.ref038","first-page":"124","article-title":"Pharmacokinetics of the macrocyclic lactones: conventional wisdom and new paradigms","volume":"97","author":"D Hennessy","year":"2002","journal-title":"Macrocyclic lactones in antiparasitic therapy."}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0011567","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T17:33:28Z","timestamp":1694021608000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011567"}},"subtitle":[],"editor":[{"given":"Timothy G.","family":"Geary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0011567","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0011567","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]}}}